Furthermore, since a few therapeutic options are available for EGFR wt/Ras-mut NSCLC, the combination of dasatinib plus MEK inhibitor selumetinib may be a valuable strategy in the clinical setting [90]. Here, MAP2K7 is linked to non-small cell lung carcinoma.